Sugi Predict

Sugi Predict / Compounds / SCHEMBL332693

SCHEMBL332693

SCHEMBL332693

Cn1nccc1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LPL P06858 12/20 0.36
▸ LIPG Q9Y5X9 12/20 0.36
▸ FFAR1 O14842 1/20 0.35
▸ COMT P21964 1/20 0.32
▸ P2RX7 Q99572 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ IRAK4 Q9NWZ3 1/20 0.31
▸ CA1 P00915 2/20 0.31
▸ CA2 P00918 2/20 0.31
▸ CA9 Q16790 2/20 0.31
▸ CA12 O43570 1/20 0.31
▸ CA3 P07451 1/20 0.31
▸ CA4 P22748 1/20 0.31
▸ CA6 P23280 1/20 0.31
▸ CA5A P35218 1/20 0.31
▸ CA7 P43166 1/20 0.31
▸ CA14 Q9ULX7 1/20 0.31
▸ CA5B Q9Y2D0 1/20 0.31
▸ MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20919403 0.87 LPL (0.33) LPLLIPGFFAR1P2RX7
SCHEMBL24664345 0.86 LPL (0.31) LPLLIPG
SCHEMBL20820951 0.85 LPL (0.32) LPLLIPGFFAR1
SCHEMBL14742735 0.85 COMT (0.31) COMTHTT
SCHEMBL24141578 0.78 LPL (0.38) LPLLIPGFFAR1P2RX7IRAK4
SCHEMBL18758896 0.77 — —
SCHEMBL1529947 0.77 LPL (0.40) LPLLIPGFFAR1
SCHEMBL19207350 0.76 FFAR1 (0.39) LPLLIPGFFAR1P2RX7
SCHEMBL1527234 0.76 SNCA (0.30) COMT
SCHEMBL1530333 0.76 LPL (0.39) LPLLIPGFFAR1P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1626 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132122-A1 6-6-FUSED BICYCLIC HETEROARYL AMINES AS CDK4 INHIBITORS INCYTE CORP (US) 2026-05-14 — — US disclosed
EP-4734979-A2 TMEM175 AGONISTS, COMPOSITIONS, AND METHODS OF USE Caraway Therapeutics, Inc. (US) 2026-05-06 — — EP disclosed
EP-4735114-A1 SUBSTITUTED THIENO [3,2-B]PYRIDINES AS INHIBITORS OF PROTEIN KINASES Masarykova Univerzita (CZ) 2026-05-06 — — EP disclosed
US-20260103471-A1 CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV ASSEMBLY BIOSCIENCES INC (US) 2026-04-16 — — US disclosed
EP-4720060-A1 PRMT5 INHIBITORS Ryvu Therapeutics S.A. (PL) 2026-04-08 — — EP disclosed
US-20260092053-A1 KHK INHIBITORS GILEAD SCIENCES INC (US) 2026-04-02 — — US disclosed
US-12590084-B2 Oxadiazole HDAC6 inhibitors and uses thereof EIKONIZO THERAPEUTICS, INC. (US) 2026-03-31 — — US disclosed
EP-4709722-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORPORATION (US) 2026-03-18 — — EP disclosed
EP-4709723-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORPORATION (US) 2026-03-18 — — EP disclosed
US-12565490-B2 Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2026-03-03 — — US disclosed
WO-2008098104-A1 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2008-08-14 — — WO disclosed
WO-2008098104-A1 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2008-08-14 — — WO disclosed
WO-2008098105-A1 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2008-08-14 — — WO disclosed
WO-2008098105-A1 INHIBITORS OF AKT ACTIVITY SMITHKLINE BEECHAM CORPORATION (US) 2008-08-14 — — WO disclosed
WO-2008078091-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2008-07-03 — — WO disclosed
WO-2008079836-A2 MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-07-03 — — WO disclosed
US-20080091027-A1 Process for producing oxazole, imidazole, pyrrazole boryl compounds BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2008-04-17 — — US disclosed
WO-2007120729-A2 PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS MERCK & CO., INC. (US) 2007-10-25 — — WO disclosed
US-7157447-B2 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-01-02 — — US disclosed
US-20060199956-A1 Bicyclic heterocycles as HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY 2006-09-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080091027-A1 Process for producing oxazole, imidazole, pyrrazole boryl compounds OXA1L, ZC3HAV1L, PBK LPL 4792/4885LIPG 4525/4885FFAR1 3801/4885
US-20260103471-A1 CYCLIC UREA THIAZOLYL COMPOUNDS FOR TREATMENT OF HSV TK1, UNG, SMCHD1 LPL 2172/4885LIPG 2329/4885FFAR1 4113/4885
US-12590084-B2 Oxadiazole HDAC6 inhibitors and uses thereof HDAC6, HDAC1, HDAC9 LPL 2822/4885LIPG 4394/4885FFAR1 4214/4885
US-20260132122-A1 6-6-FUSED BICYCLIC HETEROARYL AMINES AS CDK4 INHIBITORS CCNA1, CDK4, CCNO LPL 3977/4885LIPG 4600/4885FFAR1 2405/4885
US-20260092053-A1 KHK INHIBITORS KHK, SLC5A2, HK1 LPL 178/4885LIPG 249/4885FFAR1 180/4885
US-20060199956-A1 Bicyclic heterocycles as HIV integrase inhibitors CCNI, TYMP, IMPDH1 LPL 4812/4885LIPG 4606/4885FFAR1 4457/4885
US-12565490-B2 Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease RIPK1, RIPK4, RIPK2 LPL 3606/4885LIPG 2863/4885FFAR1 493/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.